Immunovant
Dr. Maria Alba is Vice President of Clinical Development.
Prior to joining Immunovant, from 2005 to 2019 Maria had spent 6 years at Merck and 8 years at Janssen as Senior Director in Clinical Research, holding key roles and responsibilities in all activities of Phase 2 to Phase 4 clinical development, including the design and implementation of over 20 studies of small and large molecules across multiple indications in the diabetes-metabolism area.
From 2019 to 2020, she was Executive Director at Amicus Therapeutics where she held the position of Global Medical Leader for the entire Phase 2 and 3 clinical program for the development of second generation of enzyme replacement therapy of Pompe disease.
More recently, Maria was Senior Director at Vertex Pharmaceuticals where she led the design and initiation of the First-in-Human study involving the transplant of human stem-cell derived pancreatic islets for the treatment of T1D.
Maria earned an MD from the Catholic University in Rome, Italy, where she also completed her fellowship in Endocrinology and Metabolism.
This person is not in any offices